1
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2000
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission file number 0-26872
GELTEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 04-3136767
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
153 SECOND AVENUE
WALTHAM, MASSACHUSETTS 02451
(Address of principal executive offices) (Zip Code)
781-290-5888
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes (X) No
--- ---
The number of shares outstanding of each of the issuer's classes of common stock
as of the latest practicable date:
CLASS OUTSTANDING AT AUGUST 4, 2000
----- -----------------------------
Common Stock, $.01 par value 20,551,440
2
GELTEX PHARMACEUTICALS, INC.
TABLE OF CONTENTS
PAGE NO
-------
PART I FINANCIAL INFORMATION
ITEM 1 Financial Statements
Consolidated Balance Sheets as of June 30, 2000 and December 31, 1999.............................. 3
Condensed Consolidated Statements of Operations for the three months ended 4
June 30, 2000 and 1999.............................................................................
Condensed Consolidated Statements of Operations for the six months ended 4
June 30, 2000 and 1999.............................................................................
Consolidated Statements of Comprehensive Loss for the three months ended
June 30, 2000 and 1999............................................................................. 5
Consolidated Statements of Comprehensive Loss for the six months ended June 30, 2000 and 1999...... 5
Consolidated Statements of Cash Flows for the six months ended June 30, 2000 and 1999.............. 6
Notes to Consolidated Financial Statements......................................................... 7
ITEM 2 Management's Discussion and Analysis of Financial Condition and Results of Operations............. 9
ITEM 3 Quantitative and Qualitative Disclosures About Market Risk......................................... 11
PART II OTHER INFORMATION
ITEM 4 Submission of Matters to a Vote of Security Holders................................................ 11
ITEM 6 Exhibits and Reports on Form 8-K................................................................... 12
SIGNATURE................................................................................................................ 13
EXHIBIT INDEX............................................................................................................ 14
-2-
3
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
GELTEX PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
JUNE 30, DECEMBER 31,
2000 1999
------------ -------------
ASSETS
Current assets:
Cash and cash equivalents................................................................... $ 67,402,715 $ 20,178,391
Marketable securities....................................................................... 51,684,270 52,250,534
Prepaid expenses and other current assets................................................... 4,097,180 1,763,400
Due from affiliates......................................................................... 412,050 411,250
Due from Joint Venture...................................................................... 719,054 664,741
------------ -------------
Total current assets............................................................................ 124,315,269 75,268,316
Long-term receivables, affiliates............................................................... 340,500 371,750
Property and equipment, net..................................................................... 13,846,747 11,117,725
Purchased goodwill, net......................................................................... 6,262,548 6,753,729
Intangible assets, net.......................................................................... 1,509,678 1,282,490
Investment in Joint Venture..................................................................... 14,854,744 11,295,056
Other assets.................................................................................... 2,134,551 -
------------ -------------
$163,264,067 $ 106,089,066
============ =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses...................................................... $ 3,495,337 $ 5,175,756
Current portion of long-term obligations................................................... 1,513,043 1,646,296
------------ -------------
Total current liabilities....................................................................... 5,008,380 6,822,052
Other, long-term obligations.................................................................... 563,083 5,390
Long-term obligations, less current portion..................................................... 5,848,908 6,559,884
Commitments and contingencies................................................................... - -
Stockholders' equity:
Preferred Stock, $0.01 par value, 5,000,000 shares authorized,
none issued or outstanding.................................................................. - -
Common Stock, $.01 par value, 50,000,000 shares authorized;
20,447,465 and 18,063,122 shares issued and outstanding
at June 30, 2000 and December 31, 1999, respectively........................................ 204,475 180,631
Additional paid-in capital.................................................................. 248,097,636 202,210,089
Deferred compensation....................................................................... (329,056) (483,019)
Unrealized loss on available-for-sale securities............................................ (201,851) (245,099)
Accumulated deficit......................................................................... (95,927,508) (108,960,862)
------------- -------------
Total stockholders' equity...................................................................... 151,843,696 92,701,740
------------ -------------
$163,264,067 $ 106,089,066
============ =============
The accompanying notes are an integral part of the financial statements.
-3-
4
GELTEX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
THREE MONTHS SIX MONTHS
ENDED JUNE 30, ENDED JUNE 30,
2000 1999 2000 1999
------------ ------------ ------------ ------------
Revenue:
Collaborative Joint Venture project reimbursement ......... $ 1,098,319 $ 1,078,682 $ 2,440,856 $ 2,961,596
Contract revenue .......................................... 23,064,102 -- 29,303,783 1,751,670
------------ ------------ ------------ ------------
Total revenue ................................................ 24,162,421 1,078,682 31,744,639 4,713,266
Costs and expenses:
Research and development .................................. 7,243,934 7,274,715 14,644,901 14,414,805
Collaborative Joint Venture project costs ................. 1,098,319 1,078,682 2,440,856 2,961,596
------------ ------------ ------------ ------------
Total research and development ......................... 8,342,253 8,353,397 17,085,757 17,376,401
General and administrative ................................ 1,768,562 1,392,105 3,347,570 2,610,272
------------ ------------ ------------ ------------
Total costs and expenses ..................................... 10,110,815 9,745,502 20,433,327 19,986,673
Income (loss) from operations ................................ 14,051,606 (8,666,820) 11,311,312 (15,273,407)
Interest income, net ......................................... 1,400,896 1,040,236 2,326,324 2,188,337
Equity in gain (loss) of Joint Venture ....................... 810,719 (1,789,299) (604,283) (4,067,864)
------------ ------------ ------------ ------------
Net income (loss) ............................................ $ 16,263,221 $ (9,415,883) $ 13,033,353 $(17,152,934)
============ ============ ============ ============
Basic net income (loss) per share ............................ $ 0.81 $ (0.56) $ 0.67 $ (1.02)
Shares used in computing basic net income (loss) per share ... 20,140,844 16,854,000 19,331,360 16,844,000
Diluted net income (loss) per share .......................... $ 0.79 $ (0.56) $ 0.66 $ (1.02)
Shares used in computing diluted net income (loss) per share.. 20,568,694 16,854,000 19,775,102 16,844,000
The accompanying notes are an integral part of the financial statements.
-4-
5
GELTEX PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(UNAUDITED)
THREE MONTHS SIX MONTHS
ENDED JUNE 30, ENDED JUNE 30,
2000 1999 2000 1999
------------ ------------ ------------ ------------
Net income (loss) ....................................... $ 16,263,221 $ (9,415,883) $ 13,033,353 $(17,152,934)
Other comprehensive income (loss):
Unrealized gain (loss) on securities held during
the period ...................................... 5,211 (270,643) 43,248 (424,207)
------------ ------------ ------------ ------------
Comprehensive income (loss) ............................ $ 16,268,432 $ (9,686,526) $ 13,076,601 $(17,577,141)
============ ============ ============ ============
The accompanying notes are an integral part of the financial statements.
-5-
6
GELTEX PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
SIX MONTHS
ENDED JUNE 30,
2000 1999
------------- -------------
OPERATING ACTIVITIES
Net income (loss) ........................................................................... $ 13,033,353 $ (17,152,934)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating
activities:
Depreciation and amortization ............................................................ 1,621,728 993,010
Equity in net loss of Joint Venture ...................................................... 604,283 4,067,964
Compensation from issuance of stock options .............................................. 371,423 375,738
Forgiveness of notes receivable .......................................................... 31,250 --
Changes in operating assets and liabilities:
Prepaid expenses and other current assets ............................................ (2,333,781) (112,824)
Due from Joint Venture ............................................................... (54,313) 683,445
Long-term receivables ................................................................ (2,134,551) 31,134
Accounts payable and accrued expenses ................................................ (1,680,419) (398,433)
Other long-term obligations .......................................................... 557,693 --
Amount due to Joint Venture .......................................................... -- (1,349,400)
Inventory ............................................................................ -- (3,186,133)
------------- -------------
Net cash provided by (used in) operating activities ......................................... $ 10,016,666 $ (16,048,433)
INVESTING ACTIVITIES
Purchase of marketable securities ........................................................... $(267,024,537) $ (13,285,856)
Proceeds from sale and maturities of marketable securities .................................. 267,415,789 16,098,566
Investment in Joint Venture ................................................................. (4,164,001) (7,949,303)
Purchase of intangible assets ............................................................... (447,865) (386,997)
Purchase of property and equipment, net ..................................................... (3,638,889) (650,726)
------------- -------------
Net cash used in investing activities ....................................................... $ (7,859,503) $ (6,174,316)
FINANCING ACTIVITIES
Sale of Common Stock and warrants, net of issuance costs .................................... $ 45,911,391 $ 342,331
Payments on long-term obligations ........................................................... (844,229) (1,179,806)
------------- -------------
Net cash provided by (used in) financing activities ......................................... 45,067,162 (837,475)
Increase (decrease) in cash and cash equivalents ............................................ 47,224,324 (23,060,204)
Cash and cash equivalents at beginning of period ............................................ 20,178,391 30,874,900
------------- -------------
Cash and cash equivalents at end of period .................................................. 67,402,715 $ 7,814,696
============= =============
Interest paid ............................................................................... $ 380,404 $ 259,720
The accompanying notes are an integral part of the financial statements.
-6-
7
GELTEX PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
1. NATURE OF BUSINESS
GelTex Pharmaceuticals, Inc. develops and markets non-absorbed polymer
drugs that bind and eliminate targeted substances from the gastrointestinal
tract. In addition, GelTex is developing small-molecule pharmaceuticals
consisting of novel polyamine analogues and metal chelators. Therapeutic areas
of interest include hyperphosphatemia, hypercholesterolemia, cancer, iron
overload and infectious diseases.
2. BASIS OF PRESENTATION
The accompanying unaudited consolidated financial statements of GelTex
Pharmaceuticals, Inc. and its wholly owned subsidiaries (the "Company") for the
three and six months ended June 30, 2000 and 1999, have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation
S-X. Accordingly, they do not include all the information and notes required by
generally accepted accounting principles for complete financial statements. In
the opinion of management, the accompanying consolidated financial statements
include all adjustments, consisting of normal recurring adjustments, necessary
for a fair presentation of the financial condition, results of operations and
cash flows for the periods presented. The results of operations for the interim
period ended June 30, 2000, are not necessarily indicative of the results to be
expected for the year ended December 31, 2000.
These financial statements should be read in conjunction with the audited
financial statements and notes thereto for the fiscal year ended December 31,
1999, included in the Company's Annual Report on Form 10-K (File Number 0-26872)
as filed with the Securities and Exchange Commission.
3. BUSINESS CHANGES
In July 2000, the Company was granted approval by the U.S. Food and Drug
Administration ("FDA") to market Renagel(1) (sevelamer hydrochloride) tablets in
800 mg and 400 mg dosages for the reduction of serum phosphorus in hemodialysis
patients with end-stage renal disease.
In June 2000, the Company filed an Investigational New Drug ("IND")
application for a non-absorbed toxin binding polymer, GT106-246, for the
treatment of Clostridium difficile ("C. difficile") colitis. The FDA has given
approval for human testing of GT 102-246, and a Phase 1 trial has begun.
In May 2000, the Company was granted marketing approval by the FDA for
WelChol(2) (formerly Cholestagel(3); colesevelam hydrochloride) for the
treatment of hypercholesterolemia, a condition characterized by undesirably high
cholesterol levels.
In April 2000, as part of a corporate evaluation of its research pipeline,
Warner-Lambert Company informed the Company of its intention to return all
rights to diethylnorspermine ("DENSPM"), which is in Phase 1/2 trials for solid
tumors. The Company acquired the alliance with Warner-Lambert as part of its
acquisition of SunPharm Corporation in November 1999. The Company will evaluate
its development plan for DENSPM within the context of the Company's ongoing
research on second-generation polyamine analogues as anti-cancer agents.
In early 2000, approval to market Renagel capsules, for the control of
hyperphosphatemia in the European Union and Canada, was granted.
- ---------------------------------------
(1) Renagel(R)is a registered trademark of the Company.
(2) WelChol(TM)is a trademark of Sankyo Pharma Inc., the Company's partner for
commercializing WelChol(TM).
(3) Cholestagel(R)is a registered trademark of the Company.
-7-
8
4. EQUITY FINANCINGS
In March 2000, the Company sold 1,750,000 newly issued shares of Common
Stock to certain institutional investors for net proceeds of $35.0 million. In
addition, the Company entered into an agreement with Acqua Wellington North
American Equities Fund, Ltd. ("Acqua Wellington") for a financing facility
covering the sale of up to 1,750,000 shares of Common Stock over the next twelve
months. These shares may be sold, at the Company's discretion, at a small
discount to the market price. The total amount of the investment is dependent,
in part, on the Company's stock price, with the Company to control the amount
and timing of the stock sold. These transactions were entered into pursuant to
an effective shelf registration statement previously filed by the Company with
the Securities and Exchange Commission, covering the sale of up to 3.5 million
shares of its Common Stock.
On April 3, 2000, the Company received $4.3 million in net proceeds from
the sale of 230,179 shares of its Common Stock under the financing facility with
Acqua Wellington, on June 16, 2000, the Company received $6.0 million in net
proceeds from the sale of 323,099 shares of its Common Stock under the financing
facility with Acqua Wellington and on August 8, 2000, the Company received $13.0
million from the sale of 467,498 shares of its Common Stock under the financing
facility with Acqua Wellington.
5. RECLASSIFICATION
Certain amounts from the prior year have been reclassified to conform to
the current year presentation.
6. JOINT VENTURE AGREEMENT
Effective April 1, 2000, the Company and Genzyme Corporation modified the
terms of its Joint Venture. Previous to this modification, the Joint Venture
sold product directly to customers. Under the revised terms, the Joint Venture
will sell Renagel directly to Genzyme at a discount. Genzyme will, in turn,
re-sell Renagel to customers. Additionally, Genzyme is obligated to purchase
finished goods ordered by Genzyme when such goods have been bottled. To the
extent Genzyme earns a profit on sales of Renagel to customers, GelTex's share
of the Joint Venture's net income or loss is adjusted to maintain a net 50/50
split between the two venturers. Accordingly, GelTex's share of the Joint
Venture's operations for the three months ended June 30, 2000, was a profit of
$0.8 million and GelTex's share of the Joint Venture's operations for the six
months ended June 30, 2000, was a loss of $0.6 million.
Summarized financial information regarding the Joint Venture for the three
and six months ended June 30, 2000 and June 30, 1999 is as follows:
THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30,
2000 1999 2000 1999
----------- ----------- ----------- -----------
Net sales........................................... $12,105,000 $ 4,122,000 $20,106,000 $ 7,668,000
Costs and expenses.................................. 14,183,000 1,562,000 25,121,000 3,078,000
Loss from operations................................ (2,064,000) (3,895,000) (5,000,000) (9,648,000)
Net loss............................................ (2,016,000) (3,579,000) (4,852,000) (8,136,000)
7. ACCOUNTING PRONOUNCEMENTS
In December 1999, the Securities and Exchange Commission ("SEC") issued
Staff Accounting Bulletin 101 ("SAB 101"), "Revenue Recognition in Financial
Statements" which provides guidance related to revenue recognition based on
interpretations and practices followed by the SEC. The effective date of this
Bulletin was deferred to no later than the fourth fiscal quarter beginning after
December 15, 1999. SAB 101 requires companies to report any changes in revenue
recognition as a cumulative change in accounting principle at the time of
implementation in accordance with Accounting Principles Board Opinion No. 20,
"Accounting Changes." The Company has concluded that SAB 101 will not have a
material impact on the financial position or results of operations of the
Company.
-8-
9
7. ACCOUNTING PRONOUNCEMENTS (CONTINUED)
In March 2000, the Financial Accounting Standards Board ("FASB") issued
Interpretation No. 44, "Accounting for Certain Transactions Involving Stock
Compensation, an Interpretation of APB No. 25." The Interpretation is generally
effective for transactions incurring after July 1, 2000 but applies to
repricings and some other transactions after December 15, 1998. The Company
believes this Interpretation will not have a significant effect on its
financial statements.
8. ACCOUNTING PRINCIPLES
Net Income (Loss) Per Common Share
Basic net income (loss) per common share is based on the weighted-average
number of common shares outstanding. For the three and six month periods ended
June 30, 2000, the difference between basic and diluted shares used in the
computation of earnings per share is 0.4 million weighted-average common
equivalent shares, respectively, resulting from outstanding Common Stock options
and warrants. For the three and six month periods ended June 30, 1999, diluted
net loss per common share is the same as basic net loss per common share as the
inclusion of weighted-average shares of Common Stock issuable upon exercise of
stock options and warrants would be antidilutive.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
THREE MONTHS ENDED JUNE 30, 2000 AND 1999
REVENUE
The Company earned revenue of $24.2 million during the three months ended
June 30, 2000, compared to $1.1 million earned during the three months ended
June 30, 1999. For the quarter ended June 30, 2000, $20.0 million of the revenue
earned was non-recurring milestone revenue from Sankyo Pharma Inc. earned upon
the receipt of marketing approval from the FDA for Welchol. Of the remaining
$4.2 million of revenue earned, $3.1 million represents reimbursement revenue
for research and development expenses incurred by the Company in connection with
its collaborative agreements for WelChol, its second-generation lipid-altering
product and other research programs. The remaining $1.1 million represents
reimbursement revenue earned from the Joint Venture for certain Renagel
development costs incurred by the Company. All of the $1.1 million in revenue
earned in the three months ended June 30, 1999, represents reimbursement revenue
from the Joint Venture for certain Renagel development costs incurred by the
Company.
OPERATING EXPENSES
The Company's total operating expenses for the three months ended June 30,
2000 were $10.1 million as compared to $9.7 million for the comparable period in
1999. Research and development expenses remained flat at $8.3 million for the
quarters ended June 30, 2000 and 1999. The Company expects its research and
development expenses to increase in connection with the continued regulatory
support of Renagel, regulatory and manufacturing costs associated with Welchol
and the Company's second-generation lipid-altering product, as well as for costs
incurred in connection with the Company's infectious diseases and other research
programs. General and administrative expenses increased by $0.4 million from
$1.4 million for the quarter ended June 30, 1999 to $1.8 for the quarter ended
June 30, 2000. The increase was primarily driven by higher administrative
personnel costs and business development expenses.
EQUITY IN JOINT VENTURE
Effective April 1, 2000, the Company and Genzyme Corporation modified the
terms of its Joint Venture. Previous to this modification, the Joint Venture
sold product directly to customers. Under the revised terms, the Joint Venture
will sell Renagel directly to Genzyme at a discount. Genzyme will, in turn,
re-sell Renagel to customers. Additionally, Genzyme is obligated to purchase
finished goods ordered by Genzyme when such goods have been bottled. To the
extent Genzyme earns a profit on sales of Renagel to customers, GelTex's share
of the Joint Venture's net income or loss is adjusted to maintain a net 50/50
split between the two venturers. The Company's equity in the operations of the
Joint Venture was a gain of $0.8 million for the three months ended June 30,
2000, as compared to a loss of $1.8 million for the same period in 1999. These
costs represent the Company's portion of the Joint Venture income or loss for
the relevant period.
-9-
10
INTEREST INCOME, NET
Net interest income increased to $1.4 million for the three months ended
June 30, 2000, from $1.0 million for the three months ended June 30, 1999, due
primarily to higher average cash balances available for investment.
SIX MONTHS ENDED JUNE 30, 2000 AND 1999
REVENUE
The Company earned revenue of $31.7 million during the six months ended
June 30, 2000, compared to $4.7 million earned during the six months ended June
30, 1999. For the six months ended June 30, 2000, $20.0 million of the revenue
earned was non-recurring milestone revenue from Sankyo Pharma Inc. earned upon
the receipt of FDA approval for WelChol. Of the remaining $11.7 million of
revenue earned, $6.3 million represents reimbursement revenue for research and
development expenses incurred by the Company in connection with its
collaborative agreements for WelChol, its second-generation lipid-altering
product and other research programs; $3.0 million represents a milestone payment
from Chugai Pharmaceutical Co., Ltd. related to the initiation of Phase 3
clinical trials of Renagel in Japan, and the remaining $2.4 million represents
reimbursement revenue earned from the Joint Venture for certain Renagel
development costs incurred by the Company. For the six month period ended June
30, 1999, $1.7 million of the revenue earned represented non-recurring
reimbursement from Chugai for certain Renagel development costs incurred by the
Company. The remaining $3.0 million represents reimbursement from the Joint
Venture for certain Renagel development costs incurred by the Company.
OPERATING EXPENSES
The Company's total operating expenses for the six months ended June 30,
2000 were $20.4 million compared to $20.0 million for the comparable period in
1999. Research and development expenses decreased by $0.4 million from $17.4
million for the six months ended June 30, 1999 to $17.0 million for the
comparable period in 2000. The Company expects its research and development
expenses to increase in connection with the continued regulatory support of
Renagel, regulatory and manufacturing costs associated with WelChol and the
Company's second-generation lipid-altering product, as well as for costs
incurred in connection with the Company's infectious diseases and other research
programs. General and administrative expenses increased by $0.7 million from
$2.6 million for the six months ended June 30, 1999 to $3.3 for the six months
ended June 30, 2000. The increase was primarily driven by increases in personnel
and business development expenses.
EQUITY IN JOINT VENTURE
As previously discussed, the Company and Genzyme modified the terms of the
Joint Venture effective April 1, 2000. The Company's equity in the operations of
the Joint Venture was a loss of $0.6 million for the six months ended June 30,
2000, as compared to a loss of $4.1 million for the same period in 1999. These
costs represent the Company's portion of the Joint Venture income or loss for
the relevant periods.
INTEREST INCOME, NET
Net interest income increased to $2.3 million for the six months ended June 30,
2000, from $2.2 million for the six months ended June 30, 1999 due primarily to
higher average cash balances available for investment which were partially
offset by higher interest expense.
GOODWILL
The research and development projects acquired in connection with the
acquisition of SunPharm Corporation are expected to continue in-line with the
estimates set forth in our 1999 Annual Report on Form 10-K. Goodwill is being
amortized on a straight line-basis over seven years. Amortization expense
related to this acquisition for the three and six month periods ended June 30,
2000 was approximately $0.3 million and $0.5 million, respectively.
-10-
11
LIQUIDITY AND CAPITAL RESOURCES
As of June 30, 2000, the Company had $119.1 million in cash, cash
equivalents and marketable securities as compared with $72.4 million at December
31, 1999. The net increase in cash, cash equivalents and marketable securities
from December 31, 1999, is primarily due to the receipt of $45.0 million in net
proceeds from the sale of 2.3 million shares of the Company's Common Stock to
certain institutional investors. The Company believes that its existing cash
balances and marketable securities, coupled with the proceeds from the potential
sale, if any, of the remaining 0.7 million shares of its Common Stock under its
financing facility with Acqua Wellington will be sufficient to fund its
operations through at least the year 2002.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Market risks were reported in the Notes to the Financial Statements for the
Company's Annual Report on Form 10-K for the year ended December 31, 1999. There
have been no material changes in these risks since the end of the year.
PART II. OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
The Company's 2000 Annual Meeting of Stockholders was held May 24, 2000. The
following is a description of the three matters submitted to a vote of the
stockholders at such meeting and the results of voting.
(i) At the meeting two directors were elected to serve on the Company's
Board of Directors.
Number of Shares
Number of Shares Voted Against Number of
Director Elected Voted For Or Withheld Shares Abstained
----------------- ---------------- ---------------- ----------------
J. Richard Crout 14,167,471 28,232 -
Mark Skaletsky 14,167,471 28,232 -
There were no broker non-votes with respect to this matter.
The following directors' terms of office as directors continued after the
meeting: Robert Carpenter, Henri Termeer and Jesse Treu.
(ii) The Stockholders approved an amendment to the Company's 1992 Equity
Incentive Plan to increase the number of shares of Common Stock
reserved under such plan from 3,350,000 to 4,050,000.
Number of Shares Voted For: 11,059,326
Number of Shares Voted Against or Withheld: 3,119,368
Number of Shares Abstained: -
There were no broker non-votes with respect to this matter.
(iii) The Stockholders approved an amendment to the Company's 1995 Employee
Stock Purchase Plan to increase the number of shares of Common Stock
reserved for issuance under this Plan from 50,000 to 100,000.
Number of Shares Voted For: 14,070,128
Number of Shares Voted Against or Withheld: 107,648
Number of Shares Abstained: 17,927
There were no broker non-votes with respect to this matter.
-11-
12
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits.
See the Exhibit Index on page 14 hereto.
(b) Reports on Form 8-K.
None.
-12-
13
GELTEX PHARMACEUTICALS, INC.
FORM 10-Q
JUNE 30, 2000
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
GELTEX PHARMACEUTICALS, INC.
DATE: August 14, 2000 BY: /s/ Paul J. Mellett, Jr.
-------------------------------
Paul J. Mellett, Jr.
Duly Authorized Officer and
Principal Financial Officer
-13-
14
EXHIBIT INDEX
EXHIBIT NUMBER DESCRIPTION
- -------------- -----------
10.1* Amended and Restated Collaboration Agreement among GelTex
Pharmaceuticals, Inc., Genzyme Corporation and RenaGel LLC dated
as of April 1, 2000.
10.2 Amended and Restated Operating Agreement of RenaGel LLC dated as
of April 1, 2000, by and among GelTex Pharmaceuticals, Inc.,
RenaGel Inc. and Genzyme Corporation
27.1 Financial Data Schedule
- ----------------------
*Certain confidential material contained in Exhibit 10.1 has been omitted and
filed separately with the Securities and Exchange Commission
-14-